CBER Restricts Telephone Contacts With Firms As BIO Presses For Flexibility
Executive Summary
The biologics industry may be eager to speak to FDA reviewers over the telephone, but agency guidelines make such contacts difficult for agency officials.
You may also be interested in...
Where's Your Application? FDA May Soon Have An App For That
Agency's transparency initiative may include a tracking system similar to Health Canada's so that reviewers can avoid having to field phone calls from sponsors asking about the status of an application.
PDUFA Negotiations Focus On Review Delays; Firms, FDA See Different Causes
Industry appears to be showing its strongest hand as PDUFA V negotiations roll along, laying down the cards showing FDA's poor record of meeting user fee goals in recent years
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.